Skip to main
GMED
GMED logo

Globus Medical (GMED) Stock Forecast & Price Target

Globus Medical (GMED) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 45%
Hold 9%
Sell 0%
Strong Sell 0%

Bulls say

Globus Medical is positioned for potential upside driven by faster-than-expected growth in the spine market, increased sales in its Enabling Technologies segment, and improved profit margins. The company is currently trading below historical valuation levels, with substantial double-digit free cash flow growth and an 8% free cash flow yield, suggesting appealing investment opportunities. Despite a slight miss in 2Q25 base business results, there remains optimism regarding future profits, indicating a favorable outlook for sustained revenue growth.

Bears say

The financial outlook for Globus Medical Inc is negatively impacted by several key factors, including slower-than-expected growth in the spine market and potential revenue dis-synergies resulting from the acquisition of NuVasive. Additionally, the company's enabling technologies segment has experienced weaker growth, contributing to concerns about overall revenue expansion, which is projected to decelerate to low-single digits. Furthermore, anticipated challenges related to new product launches, competitive dynamics in the spine market, and possible declines in operating margins all pose risks to the firm’s financial performance.

Globus Medical (GMED) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 45% recommend Buy, 9% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Globus Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Globus Medical (GMED) Forecast

Analysts have given Globus Medical (GMED) a Buy based on their latest research and market trends.

According to 11 analysts, Globus Medical (GMED) has a Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $88.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $88.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Globus Medical (GMED)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.